AWARD-7 trial results

Inclusion Criteria: * Men and non-pregnant women aged ≥18 years * Hemoglobin A1c (HbA1c) ≥7.5% and ≤10.5% * Type 2 diabetes on insulin or insulin + oral antihyperglycemic medication * Participants with presumed diabetic kidney disease with or without hypertensive nephrosclerosis diagnosed with moderate or severe CKD with estimated glomerular filtration rate (eGFR) of ≥15 to \<60 milliliters per minute (mL/min)/1.73 meter squared (m\^2) * Able and willing to perform multiple daily injections * Body mass index (BMI) between 23 and 45 kilogram/square meter (kg/m\^2) Exclusion Criteria: * Stage 5 CKD as defined by eGFR \<15 mL/min/1.73 m\^2 OR having required dialysis * Rapidly progressing renal dysfunction likely to require renal replacement * History of a transplanted organ * Type 1 diabetes mellitus * At screening a systolic blood pressure of ≥150 mmHg or a diastolic blood pressure of ≥90 mmHg with or without antihypertensive medication * An episode of ketoacidosis or hyperosmolar state/coma in the past 6 months or a history of severe hypoglycemia in the past 3 months prior to the Screening Visit * Cardiovascular conditions within 12 weeks prior to randomization: acute myocardial infarction, New York Heart Association (NYHA) class III or class IV heart failure, or cerebrovascular accident (stroke) * Acute or chronic hepatitis * Signs and symptoms of chronic or acute pancreatitis, or were in the past diagnosed with pancreatitis * Serum calcitonin ≥35 picograms per milliliter (pg/mL) at Screening Visit * Self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma * Known history of untreated proliferative retinopathy